High expression of class III β-tubulin in small cell lung carcinoma

Steven Powell, Alex Kaizer, Joseph S. Koopmeiners, Carlos Iwamoto, Mark Klein

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Class III β-tubulin (TUBB3) is emerging as a biomarker in a number of cancers. TUBB3 has been shown to be a prognostic indicator of more aggressive disease and a predictor of resistance to taxanes and vinca alkaloids. To date, there is little data on TUBB3 expression in small cell lung carcinoma (SCLC). The primary objective of this study was to determine the expression of TUBB3 in SCLC. Immunohistochemical staining of SCLC tumor specimens was performed using standard procedures. Expression of TUBB3 was determined as a composite of the percentage of malignant cells staining positive and the intensity of staining. Clinical and tumor data for each patient was compared with the degree of TUBB3 expression. A total of 66 SCLCs were evaluable for TUBB3 expression. The majority of specimens (n=56, 85%) had high expression of TUBB3. Only 4.5% (n=3) had low expression of TUBB3. The mean distribution of positive staining for the specimens was 87.3±1.8% (mean ± SE). Specimens from core biopsies were significantly more likely to have high TUBB3 expression when compared with fine needle aspirates (P=0.004). There were no other significant findings when comparing clinical or tumor characteristics. Overall, we found that expression of TUBB3 in SCLC is higher than expected. Innate resistance to microtubule inhibitors, such as the taxanes and vinca alkaloids, may be associated with this finding. Attempts at microtubule inhibition with novel agents may be able to overcome this resistance mechanism. Further evaluation of TUBB3 as a biomarker in SCLC is warranted.

Original languageEnglish (US)
Pages (from-to)405-410
Number of pages6
JournalOncology Letters
Volume7
Issue number2
DOIs
StatePublished - Feb 1 2014

Fingerprint

Small Cell Lung Carcinoma
Tubulin
Vinca Alkaloids
Staining and Labeling
Taxoids
Microtubules
Neoplasms
Biomarkers
Needles
Biopsy

Keywords

  • Class III ß-tubulin
  • Microtubule inhibitor
  • Small cell lung carcinoma

Cite this

High expression of class III β-tubulin in small cell lung carcinoma. / Powell, Steven; Kaizer, Alex; Koopmeiners, Joseph S.; Iwamoto, Carlos; Klein, Mark.

In: Oncology Letters, Vol. 7, No. 2, 01.02.2014, p. 405-410.

Research output: Contribution to journalArticle

Powell, Steven ; Kaizer, Alex ; Koopmeiners, Joseph S. ; Iwamoto, Carlos ; Klein, Mark. / High expression of class III β-tubulin in small cell lung carcinoma. In: Oncology Letters. 2014 ; Vol. 7, No. 2. pp. 405-410.
@article{35bc28c2db3945b7858c828f5b3a0d68,
title = "High expression of class III β-tubulin in small cell lung carcinoma",
abstract = "Class III β-tubulin (TUBB3) is emerging as a biomarker in a number of cancers. TUBB3 has been shown to be a prognostic indicator of more aggressive disease and a predictor of resistance to taxanes and vinca alkaloids. To date, there is little data on TUBB3 expression in small cell lung carcinoma (SCLC). The primary objective of this study was to determine the expression of TUBB3 in SCLC. Immunohistochemical staining of SCLC tumor specimens was performed using standard procedures. Expression of TUBB3 was determined as a composite of the percentage of malignant cells staining positive and the intensity of staining. Clinical and tumor data for each patient was compared with the degree of TUBB3 expression. A total of 66 SCLCs were evaluable for TUBB3 expression. The majority of specimens (n=56, 85{\%}) had high expression of TUBB3. Only 4.5{\%} (n=3) had low expression of TUBB3. The mean distribution of positive staining for the specimens was 87.3±1.8{\%} (mean ± SE). Specimens from core biopsies were significantly more likely to have high TUBB3 expression when compared with fine needle aspirates (P=0.004). There were no other significant findings when comparing clinical or tumor characteristics. Overall, we found that expression of TUBB3 in SCLC is higher than expected. Innate resistance to microtubule inhibitors, such as the taxanes and vinca alkaloids, may be associated with this finding. Attempts at microtubule inhibition with novel agents may be able to overcome this resistance mechanism. Further evaluation of TUBB3 as a biomarker in SCLC is warranted.",
keywords = "Class III {\ss}-tubulin, Microtubule inhibitor, Small cell lung carcinoma",
author = "Steven Powell and Alex Kaizer and Koopmeiners, {Joseph S.} and Carlos Iwamoto and Mark Klein",
year = "2014",
month = "2",
day = "1",
doi = "10.3892/ol.2013.1734",
language = "English (US)",
volume = "7",
pages = "405--410",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - High expression of class III β-tubulin in small cell lung carcinoma

AU - Powell, Steven

AU - Kaizer, Alex

AU - Koopmeiners, Joseph S.

AU - Iwamoto, Carlos

AU - Klein, Mark

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Class III β-tubulin (TUBB3) is emerging as a biomarker in a number of cancers. TUBB3 has been shown to be a prognostic indicator of more aggressive disease and a predictor of resistance to taxanes and vinca alkaloids. To date, there is little data on TUBB3 expression in small cell lung carcinoma (SCLC). The primary objective of this study was to determine the expression of TUBB3 in SCLC. Immunohistochemical staining of SCLC tumor specimens was performed using standard procedures. Expression of TUBB3 was determined as a composite of the percentage of malignant cells staining positive and the intensity of staining. Clinical and tumor data for each patient was compared with the degree of TUBB3 expression. A total of 66 SCLCs were evaluable for TUBB3 expression. The majority of specimens (n=56, 85%) had high expression of TUBB3. Only 4.5% (n=3) had low expression of TUBB3. The mean distribution of positive staining for the specimens was 87.3±1.8% (mean ± SE). Specimens from core biopsies were significantly more likely to have high TUBB3 expression when compared with fine needle aspirates (P=0.004). There were no other significant findings when comparing clinical or tumor characteristics. Overall, we found that expression of TUBB3 in SCLC is higher than expected. Innate resistance to microtubule inhibitors, such as the taxanes and vinca alkaloids, may be associated with this finding. Attempts at microtubule inhibition with novel agents may be able to overcome this resistance mechanism. Further evaluation of TUBB3 as a biomarker in SCLC is warranted.

AB - Class III β-tubulin (TUBB3) is emerging as a biomarker in a number of cancers. TUBB3 has been shown to be a prognostic indicator of more aggressive disease and a predictor of resistance to taxanes and vinca alkaloids. To date, there is little data on TUBB3 expression in small cell lung carcinoma (SCLC). The primary objective of this study was to determine the expression of TUBB3 in SCLC. Immunohistochemical staining of SCLC tumor specimens was performed using standard procedures. Expression of TUBB3 was determined as a composite of the percentage of malignant cells staining positive and the intensity of staining. Clinical and tumor data for each patient was compared with the degree of TUBB3 expression. A total of 66 SCLCs were evaluable for TUBB3 expression. The majority of specimens (n=56, 85%) had high expression of TUBB3. Only 4.5% (n=3) had low expression of TUBB3. The mean distribution of positive staining for the specimens was 87.3±1.8% (mean ± SE). Specimens from core biopsies were significantly more likely to have high TUBB3 expression when compared with fine needle aspirates (P=0.004). There were no other significant findings when comparing clinical or tumor characteristics. Overall, we found that expression of TUBB3 in SCLC is higher than expected. Innate resistance to microtubule inhibitors, such as the taxanes and vinca alkaloids, may be associated with this finding. Attempts at microtubule inhibition with novel agents may be able to overcome this resistance mechanism. Further evaluation of TUBB3 as a biomarker in SCLC is warranted.

KW - Class III ß-tubulin

KW - Microtubule inhibitor

KW - Small cell lung carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84890330544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890330544&partnerID=8YFLogxK

U2 - 10.3892/ol.2013.1734

DO - 10.3892/ol.2013.1734

M3 - Article

VL - 7

SP - 405

EP - 410

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 2

ER -